The Great Rotation: money is fleeing AI bagholders and waddling straight into fat-loss drugs 💉🚀

Alright regards, gather round. Something actually happened this week besides my puts expiring worthless.

The setup: Nasdaq just printed its 5th straight red day. The AI infinite-money-glitch trade is wobbling. OpenAI is reportedly thinking about pushing its IPO to next year, and suddenly everyone remembered that “spend $500B on GPUs and figure out revenue later” might not be a plan. Chips got smoked. Apple and Microsoft eating losses on their own drama.

So where did the smart money run? Defensives. And healthcare specifically caught a real bid, second-best sector on the week with the equal-weight index climbing, meaning it’s not just 7 megacaps holding the tape up anymore. This is what a rotation looks like before it’s obvious.

Enter the fat-loss summer body cartel. 💊

Novo (NVO) is the degenerate value play here. Stock got absolutely beaten like it owed someone money, down \~65% from the 2024 top, max drawdown over 50% in March after a CagriSema miss and two guidance cuts. But the tape is turning:

• Oral Wegovy lands in the UK July 6th. First GLP-1 pill for weight loss in Europe.

• Chemist4U alone reportedly has a 10,000+ waitlist, and \~75% have NEVER touched a GLP-1. That’s not stealing Lilly’s customers, that’s growing the whole pie.

• EU gave the pill a positive regulator opinion in May, EC approval pending, launches in Germany / Denmark / UK in 6. Juli. Already.

• It bounced \~6% on the UK approval and closed Friday green while tech bled.

Eli Lilly (LLY) is still the 800lb gorilla, don’t get it twisted. Mounjaro + Zepbound did \~$36B last year and Lilly’s guiding to \~28% growth while Novo guides to a decline. Their oral, Foundayo, is ramping slower because it’s a new molecule/brand, and orforglipron is the wildcard. If you want the quality compounder, it’s LLY. If you want the beaten-down turnaround lottery ticket, it’s NVO.

The bear case (because I’m not totally smooth-brained): Novo’s own 2026 guidance is a sales DECLINE of 4-12%. US pricing is eroding. Lilly is taking share. Analysts are mostly Hold (like 5 Buy / 9 Hold, zero Sell, aka “we have no idea”). The pill demand is real but the metric that matters is whether people stay on it through the dose ramp.

The catalyst: Novo Q2 earnings August 5th. Pill retention numbers will either send it or end it.

TL;DR: AI bubble leaking air, money rotating defensive, healthcare bid, and the GLP-1 pill war is going global. NVO = turnaround YOLO, LLY = the safe-ish chad play.

Positions: long both because I refuse to pick a side in a knife fight. NFA, I eat crayons. 🖍️🐂